PLAZOMICIN SULFATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for plazomicin sulfate and what is the scope of patent protection?
Plazomicin sulfate
is the generic ingredient in one branded drug marketed by Cipla Usa and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Plazomicin sulfate has twenty-eight patent family members in twenty-one countries.
Three suppliers are listed for this compound.
Summary for PLAZOMICIN SULFATE
International Patents: | 28 |
US Patents: | 4 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 9 |
Patent Applications: | 4 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for PLAZOMICIN SULFATE |
DailyMed Link: | PLAZOMICIN SULFATE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PLAZOMICIN SULFATE
Generic Entry Date for PLAZOMICIN SULFATE*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for PLAZOMICIN SULFATE
US Patents and Regulatory Information for PLAZOMICIN SULFATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for PLAZOMICIN SULFATE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Lithuania | 2217610 | ⤷ Sign Up | |
South Korea | 20100110297 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ⤷ Sign Up |
South Korea | 101296099 | ⤷ Sign Up | |
European Patent Office | 3150617 | ANALOGUES D'AMINOGLYCOSIDES ANTIBACTÉRIENS (ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS) | ⤷ Sign Up |
European Patent Office | 2217610 | ANALOGUES D'AMINOGLYCOSIDES ANTIBACTÉRIENS (ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |